Roche's CNS Drug Pipeline Matures: More Investment, More Promise
Executive Summary
Roche Holding AG has established itself as a leader in areas like oncology, infectious disease, liver disease and inflammatory disease. Now, the company is eyeing the central nervous system as a new frontier for its R&D, stealthily building a considerable clinical-stage pipeline in the process.
You may also be interested in...
Roche’s Kadcyla Fails To Better Herceptin In First-Line Breast Cancer
Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer. Firm’s early Alzheimer’s therapy gantenerumab also fails in Phase III.
Roche Says Kadcyla Fails To Better Herceptin In First-Line Breast Cancer
Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer.
Roche Third-Quarter Pipeline Adjustments Include Advancements, Delays
Roche adjusted regulatory expectations for its pipeline during a third-quarter earnings call Oct. 16, moving up filing plans for onartuzumab (MetMAb) in metastatic non-small cell lung cancer to 2014 and pushing back an ocrelizumab filing in multiple sclerosis to 2015, both based on trial enrollment rates.